Abstract:Objective Amyotrophic lateral sclerosis (ALS) is a devastating, incurable neurodegenerative disease. A subset of ALS patients manifests with early‐onset and complex clinical phenotypes. We aimed to elucidate the genetic basis of these cases to enhance our understanding of disease etiology and facilitate the development of targeted therapies. Methods Our research commenced with an in‐depth genetic and biochemical investigation of two specific families, each with a member diagnosed with early‐onset ALS (onset age of <40 years). This involved whole‐exome sequencing, trio analysis, protein structure analysis, and sphingolipid measurements. Subsequently, we expanded our analysis to 62 probands with early‐onset ALS and further included 440 patients with adult‐onset ALS and 1163 healthy controls to assess the prevalence of identified genetic variants. Results We identified heterozygous variants in the serine palmitoyltransferase long chain base subunit 2 (SPTLC2) gene in patients with early‐onset ALS. These variants, located in a region closely adjacent to ORMDL3, bear similarities to SPTLC1 variants previously implicated in early‐onset ALS. Patients with ALS carrying these SPTLC2 variants displayed elevated plasma ceramide levels, indicative of increased serine palmitoyltransferase (SPT) activity leading to sphingolipid overproduction. Interpretation Our study revealed novel SPTLC2 variants in patients with early‐onset ALS exhibiting frontotemporal dementia. The combination of genetic evidence and the observed elevation in plasma ceramide levels establishes a crucial link between dysregulated sphingolipid metabolism and ALS pathogenesis. These findings expand our understanding of ALS's genetic diversity and highlight the distinct roles of gene defects within SPT subunits in its development.

Mutation Screening of SPTLC1 and SPTLC2 in Amyotrophic Lateral Sclerosis

SPTLC1 p.Leu38Arg, a novel mutation associated with childhood ALS

Mutation and Clinical Analysis of the CLCC1 Gene in Amyotrophic Lateral Sclerosis Patients from Central South China.

Mutation Spectrum of Chinese Patients with Familial and Sporadic Amyotrophic Lateral Sclerosis

Mutation Screening of ATXN1, ATXN2, and ATXN3 in Amyotrophic Lateral Sclerosis

Mutation screening and burden analysis of GLT8D1 in Chinese patients with ALS

SPTLC2 variants are associated with early‐onset ALS and FTD due to aberrant sphingolipid synthesis

Clinical Features and Cu/Zn Superoxide Dismutase Gene Mutations in Two Mainland Chinese Families with Amyotrophic Lateral Sclerosis

Genotype-phenotype correlation of SQSTM1 variants in patients with amyotrophic lateral sclerosis

Recurrent de-novo gain-of-function mutation in SPTLC2 confirms dysregulated sphingolipid production to cause juvenile amyotrophic lateral sclerosis

Screening of SOD1, FUS and TARDBP Genes in Patients with Amyotrophic Lateral Sclerosis in Central-Southern China.

Mutation screening and burden analysis of GLT8D1 in Chinese patients with amyotrophic lateral sclerosis

Identify Mutation in Amyotrophic Lateral Sclerosis Cases Using HaloPlex Target Enrichment System

Mutation Screening of TFG in Α‐synucleinopathy and Amyotrophic Lateral Sclerosis

Investigation of a Fused in Sarcoma Splicing Mutation in a Chinese Amyotrophic Lateral Sclerosis Patient.

Mutation Screening of the GLE1 Gene in a Large Chinese Cohort of Amyotrophic Lateral Sclerosis Patients

Presence of Rare Variants is Associated with Poorer Survival in Chinese Patients with Amyotrophic Lateral Sclerosis.

Lack of Association of TP73 Rare Variants with Amyotrophic Lateral Sclerosis in a Chinese Cohort

A de novo c.113 T > C: p.L38R mutation of SPTLC1: case report of a girl with sporadic juvenile amyotrophic lateral sclerosis

Screening for TUBA4A mutations in a large Chinese cohort of patients with ALS: re-evaluating the pathogenesis of TUBA4A in ALS

Rare CYLD Variants in Chinese Patients with Amyotrophic Lateral Sclerosis